We compared the level of IGF1R/PCNA signals with the overall mutational burden (by ranking, S1 Table) of the primary tumors (without neoadjuvant treatment) as determined by the tumor subgroup as described by Chalmers et al. [17]. This evidence concerns the gene IGF1R and neoplasm.